Chemical tuning enhances both potency toward Nrf2 and in vitro therapeutic index of triterpenoids

Toxicological Sciences

Volumn 140, Issue 2, 2014, Pages 462-469

  Copple, Ian M ^a   Shelton, Luke M ^a   Walsh, Joanne ^a   Kratschmar, Denise V ^b   Lister, Adam ^b   Odermatt, Alex ^b   Goldring, Christopher E ^a   Dinkova Kostova, Albena T ^c   Honda, Tadashi ^d   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Nrf2; Therapeutic index; Triterpenoids

Indexed keywords

BARDOXOLONE METHYL; FUMARIC ACID DIMETHYL ESTER; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LUCIFERASE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; TRITERPENE;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; CELL DEATH; CELL VIABILITY; CHEMICAL MODIFICATION; ELECTROPHILICITY; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LC50; MOUSE; NONHUMAN; RAT; SPECIES CONSERVATION; THERAPEUTIC INDEX; ANIMAL; CELL LINE; METABOLISM;

ANIMALS; CELL LINE; HUMANS; IN VITRO TECHNIQUES; MICE; NF-E2-RELATED FACTOR 2; RATS; TRITERPENES;

EID: 84984972136     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu080     Document Type: Article

References (30)

1. Bensasson, R. V., Zoete, V., Berthier, G., Talalay, P., and Dinkova-Kostova, A. T. (2010). Potency ranking of triterpenoids as inducers of a cytoprotective enzyme and as inhibitors of a cellular inflammatory response via their electron affinity and their electrophilicity index. Chem. Biol. Interact. 186, 118-126.
2. Bryan, H. K., Olayanju, A., Goldring, C. E., and Park, B. K. (2013). The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem. Pharmacol. 85, 705-717.
3. Copple, I. M., Goldring, C. E., Kitteringham, N. R., and Park, B. K. (2008). The Nrf2-Keapl defence pathway: Role in protection against drug-induced toxicity. Toxicology 246, 24-33.
4. Couch, R. D., Browning, R. G., Honda, T., Gribble, G. W., Wright, D. L., Sporn, M. B., and Anderson, A. C. (2005). Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: Implications for a molecular mechanism of action. Bioorg. Med. Chem. Lett. 15, 2215-2219.
5. de Zeeuw, D., Akizawa, T.,Audhya, P., Bakris,G. L., Chin,M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492-2503.
6. Dinkova-Kostova, A. T., Jenkins, S. N., Wehage, S. L., Huso, D. L., Benedict, A. L., Stephenson, K. K., Fahey, J. W., Liu, H., Liby, K. T., Honda, T., et al. (2008). A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. Biochem. Biophys. Res. Commun. 367, 859-865.
7. Dinkova-Kostova,A. T., Liby, K. T., Stephenson, K. K., Holtzclaw,W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005). Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. U.S.A. 102, 4584-4589.
8. Dinkova-Kostova, A. T., Massiah, M. A., Bozak, R. E., Hicks, R. J., and Talalay, P. (2001). Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. U.S.A. 98, 3404-3409.
9. Hinson, J. A., Roberts, D. W., and James, L. P. (2010). Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 196, 369-405.
10. Honda, T., Honda, Y., Favaloro, F. G., Jr, Gribble, G. W., Suh, N., Place, A. E., Rendi, M. H., and Sporn, M. B. (2002). A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett. 12, 1027-1030.
11. Honda, T., Rounds, B. V., Bore, L., Finlay, H. J., Favaloro, F. G., Jr, Suh, N., Wang, Y., Sporn, M. B., and Gribble, G. W. (2000). Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43, 4233-4246.
12. Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012). A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396-3406.
13. Houghton, C. A., Fassett, R. G., and Coombes, J. S. (2013). Sulforaphane: Translational research from laboratory bench to clinic. Nutr. Rev. 71, 709-726.
14. Hu, C., Eggler, A. L., Mesecar, A. D., and van Breemen, R. B. (2011). Modification of keap1 cysteine residues by sulforaphane. Chem. Res. Toxicol. 24, 515-521.
15. Hu, C., Nikolic, D., Eggler, A. L., Mesecar, A. D., and van Breemen, R. B. (2012). Screening for natural chemoprevention agents that modify human Keap1. Anal. Biochem. 421, 108-114.
16. Kratschmar, D. V., Calabrese, D., Walsh, J., Lister, A., Birk, J., Appenzeller-Herzog, C., Moulin, P., Goldring, C. E., and Odermatt, A. (2012). Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11beta-HSD1-mediated glucocorticoid activation in hepatic cells. PLoS One 7, e36774.
17. Lee, D. H., Stangel, M., Gold, R., and Linker, R. A. (2013). The fumaric acid ester BG-12: A new option in MS therapy. Expert Rev. Neurother. 13, 951-958.
18. Liby, K. T., and Sporn, M. B. (2012). Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972-1003.
19. Linker, R. A., Lee, D. H., Ryan, S., van Dam, A.M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678-692.
20. Ma, Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53, 401-426.
21. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011). Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10, 292-306.
22. Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336.
23. Rossing, P. (2013). Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted? Nat. Rev. Nephrol. 9, 128-130.
24. Ruiz, S., Pergola, P. E., Zager, R. A., and Vaziri, N. D. (2013). Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83, 1029-1041.
25. Shelton, L. M., Park, B. K., and Copple, I. M. (2013). Role of Nrf2 in protection against acute kidney injury. Kidney Int. 84, 1090-1095.
26. Suzuki, T., Motohashi, H., and Yamamoto, M. (2013). Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34, 340-346.
27. Talalay, P., De Long, M. J., and Prochaska, H. J. (1988). Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 85, 8261-8265.
28. Tayek, J. A., and Kalantar-Zadeh, K. (2013). The extinguished BEACON of bardoxolone: Not a Monday morning quarterback story. Am. J. Nephrol. 37, 208-211.
29. Wu, J. H., Miao, W., Hu, L. G., and Batist, G. (2010). Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1. Chem. Biol. Drug Des. 75, 475-480.
30. Zhang, D. D. (2013). Bardoxolone brings Nrf2-based therapies to light. Antioxid. Redox Signal. 19, 517-518.